報價延遲最少15分鐘:2025/02/26 19:19 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.66 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.02/0.14
|
|
企業價值
418.10M
|
| 資產負債 |
|
每股賬面淨值
0.45
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
83.57M
|
|
每股收益
1.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/26 19:19 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment. |